Quidel (QDEL) announced over the weekend that it received FDA clearance for the sale diagnostic testing products related to detecting influenza and human metapneumovirus. William Blair (Outperform) sees the announcements as evidence Quidel is on its way to transitioning from being a "pipeline story" to an "execution story."
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs